SPONSOR
Dana-Farber Cancer Institute
Total Trials
12
Recruiting
12
Phases
Phase 2, Phase 1, EARLY_Phase 1
Conditions studied: CancerLung CancerGenetic DiseaseGenetic PredispositionHereditary DiseasesGastrointestinal CancerGynecologic CancerAdvanced CancerEndometrial CancerRecurrent Endometrial Cancer
Dana-Farber Cancer Institute is a clinical research sponsor with 12 registered studies on ClinicalTrials.gov, of which 12 are actively recruiting participants. Research covers conditions including Cancer, Lung Cancer, Genetic Disease, Genetic Predisposition.
The trial portfolio spans Phase 2, Phase 1, EARLY_Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Dana-Farber Cancer Institute
How many clinical trials has Dana-Farber Cancer Institute sponsored?
ClinicalMetric currently tracks 12 clinical trials sponsored by Dana-Farber Cancer Institute, of which 12 are actively recruiting participants. These trials cover conditions including Cancer, Lung Cancer, Genetic Disease. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Dana-Farber Cancer Institute research focus on?
Dana-Farber Cancer Institute clinical trials span Cancer, Lung Cancer, Genetic Disease, Genetic Predisposition, Hereditary Diseases, and additional conditions. The research pipeline includes Phase 2, Phase 1, EARLY_Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Dana-Farber Cancer Institute clinical trial?
To participate in a Dana-Farber Cancer Institute trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Dana-Farber Cancer Institute trials with current recruitment status updated daily.
Clinical Trials by Dana-Farber Cancer Institute
NCT03310879 Phase 2
Recruiting
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
Cancer
NCT05587439
Recruiting
Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
Lung Cancer
NCT06936878
Recruiting
BOLSTER: Learning New Skills to Thrive
Gastrointestinal Cancer
NCT06366347 Phase 2
Recruiting
ALPINE: Maintenance Letrozole/Abemaciclib
Endometrial Cancer
NCT02269592
Recruiting
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Monoclonal Gammopathy of Undetermined Significance (MGUS)
NCT03689595
Recruiting
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Multiple Myeloma
NCT04024761 Phase 1
Recruiting
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Acute Myeloid Leukemia
NCT06122896 EARLY_Phase 1
Recruiting
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Pancreatic Cancer
NCT06831552
Recruiting
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
Neuroblastoma
NCT05225428
Recruiting
Video Education With Result Dependent dIsclosure
Genetic Testing
NCT04724499
Recruiting
Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy
Breast Cancer
NCT06736548
Recruiting
Sleep Treatment Education Program for Cancer Survivors: STEP-Together
Insomnia
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology